The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press6310.17650/1818-8338-2012-1-10-14REVIEWОБЗОРTHE SIGNIFICANCE OF C‑REACTIVE PROTEIN IN SYSTEMIC LUPUS ERYTHEMATOSUSЗНАЧЕНИЕ С‑РЕАКТИВНОГО БЕЛКА ПРИ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКЕNoskovS. M.НосковС. М.
Russian Federation

Chair of hospital therapy

Кафедра госпитальной терапии

VasilevskajaO. A.ВасилевскаяО. А.
Russian Federation

Chair of hospital therapy

Кафедра госпитальной терапии

NoskovaT. S.НосковаТ. С.
Russian Federation

Chair of hospital therapy

Кафедра госпитальной терапии

ArzimanovaN. A.АрзимановаН. А.
Russian Federation

Chair of hospital therapy

Кафедра госпитальной терапии

Yaroslavl state medical academy, Ministry of Health and Social Development of RussiaГОУ ВПО ЯГМУ Минздравсоцразвития России150120126110141507201415072014Copyright ©; 2012, Noskov S.M., Vasilevskaja O.A., Noskova T.S., Arzimanova N.A.Copyright ©; 2012, Носков С.М., Василевская О.А., Носкова Т.С., Арзиманова Н.А.2012Noskov S.M., Vasilevskaja O.A., Noskova T.S., Arzimanova N.A.Носков С.М., Василевская О.А., Носкова Т.С., Арзиманова Н.А.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/63

It is believed that the concentration of C‑reactive protein (CRP) significantly increases in acute forms of systemic lupus erythematosus (SLE). A moderate increase of CRP levels in patients with stable disease progression reflects the low‑grade chronic inflammation in the vascular wall and the development of subclinical atherosclerosis. The article presents data showing that increased CRP levels in SLE patients is not statistically related with disease activity and cardiovascular risk as well as the level of interleykin‑6. Patients with lupus nephritis have lower CRP concentration compared to patients without renal disease and CRP concentration depends on proteinuria and hypoalbuminemia.

Считается, что концентрация С‑реактивного белка (СРБ) значительно повышается при острых формах системной красной волчанки (СКВ), а умеренное возрастание уровня СРБ у больных со стабильным течением отражает вялотекущее хроническое воспаление в сосудистой стенке и развитие субклинического атеросклероза. В статье приводятся данные, показывающие, что повышение концентрации СРБ у больных СКВ статистически не связано с активностью заболевания и сердечно-сосудистым риском, а также с уровнем интерлейкина‑6. У больных с волчаночным нефритом концентрация СРБ снижена по сравнению с данным показателем у пациентов без почечной патологии и находится в математической зависимости с протеинурией и гипоальбуминемией.

C‑reactive proteinsystemic lupus erythematosusС‑реактивный белоксистемная красная волчанка1. Ревматология: Клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР‑Медиа; 2011.Ревматология: Клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР‑Медиа; 2011.2. Karadag O., Calguneri M., Atalar E., et al. Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients. Clin Rheumatol 2007;Karadag O., Calguneri M., Atalar E., et al. Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients. Clin Rheumatol 2007;26(5):695−9.(5):695−9.3. Jialal K., Devaraj S., Venugopal S.K. C‑reactive protein: Risk marker or mediator in atherothrombosis? Hypertension 2004;44:6−11.Jialal K., Devaraj S., Venugopal S.K. C‑reactive protein: Risk marker or mediator in atherothrombosis? Hypertension 2004;44:6−11.4. Насонов Е.Л., Попкова Т.В. Кардиоваскулярные проблемы ревматологии. Научно-практическая ревматология 2004;(4):4−9.Насонов Е.Л., Попкова Т.В. Кардиоваскулярные проблемы ревматологии. Научно-практическая ревматология 2004;(4):4−9.5. Breda L., Nozzi M., De Sanctis S., Chiarelli F. Laboratory tests in the diagnosis and follow‑up of pediatric rheumatic diseases: an update. Semin Arthritis Rheum 2010;40(1):53−72.Breda L., Nozzi M., De Sanctis S., Chiarelli F. Laboratory tests in the diagnosis and follow‑up of pediatric rheumatic diseases: an update. Semin Arthritis Rheum 2010;40(1):53−72.6. Sjöwall C., Wetterö J. Pathogenic implications for autoantibodies against C‑reactive protein andSjöwall C., Wetterö J. Pathogenic implications for autoantibodies against C‑reactive protein andother acute phase proteins. Clin Chim Acta 2007; 378(1−2):13−23.7. Marnell L., Mold C., Du Clos T.W. C‑reactive protein: ligands, receptors and role in inflammation.Marnell L., Mold C., Du Clos T.W. C‑reactive protein: ligands, receptors and role in inflammation.Clin Immunol 2005;117(2):104−11.8. Rhodes B., Fürnrohr B.G., Vyse T.J. C‑reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol 2011;7(5):282−9.Rhodes B., Fürnrohr B.G., Vyse T.J. C‑reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol 2011;7(5):282−9.9. Shih P.B., Manzi S., Shaw P., et al. Genetic variation in C‑reactive protein (CRP) gene may be associated with risk of systemic lupus erythematosus and CRP concentrations. J Rheumatol 2008;35(11):2171−8.Shih P.B., Manzi S., Shaw P., et al. Genetic variation in C‑reactive protein (CRP) gene may be associated with risk of systemic lupus erythematosus and CRP concentrations. J Rheumatol 2008;35(11):2171−8.10. Юнонин И.Е., Бутусова С.В., Шилкина Н.П. Маркеры активации эндотелия при системной красной волчанке. Цитокины и воспаление 2011;(1):26−9.Юнонин И.Е., Бутусова С.В., Шилкина Н.П. Маркеры активации эндотелия при системной красной волчанке. Цитокины и воспаление 2011;(1):26−9.11. Панафидина Т.А., Попкова Т.В., Алекберова З.С. и др. Значение факторов риска и С‑реактивного белка в развитии атеросклероза у женщин с системой красной волчанкой. Клиническая медицина 2006; 84(10):49−54.Панафидина Т.А., Попкова Т.В., Алекберова З.С. и др. Значение факторов риска и С‑реактивного белка в развитии атеросклероза у женщин с системой красной волчанкой. Клиническая медицина 2006; 84(10):49−54.12. Rezaieyazdi Z., Sahebari M., Hatef M.R., еt al. Is there any correlation between high sensitiveRezaieyazdi Z., Sahebari M., Hatef M.R., еt al. Is there any correlation between high sensitiveCRP and disease activity in systemic lupus erythematosus? Lupus 2011; 20(14):1494−500.13. Amezcua‑Guerra L.M., Springall R., Arrieta‑Alvarado A.A., et al. C‑reactive protein and complement components but not other acute‑phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus. Clin Lab 2011;57(7−8):607−13.Amezcua‑Guerra L.M., Springall R., Arrieta‑Alvarado A.A., et al. C‑reactive protein and complement components but not other acute‑phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus. Clin Lab 2011;57(7−8):607−13.14. Amezcua‑Guerra L.M., Márquez‑Velasco R., Bojalil R. Erosive arthritis in systemic lupus erythematosus is associated with high serumC‑reactive protein and anti‑cyclic citrullinated peptide antibodies. Inflamm Res 2008; 57(12):555−7.Amezcua‑Guerra L.M., Márquez‑Velasco R., Bojalil R. Erosive arthritis in systemic lupus erythematosus is associated with high serumC‑reactive protein and anti‑cyclic citrullinated peptide antibodies. Inflamm Res 2008; 57(12):555−7.15. Lozovoy M.A., Simão A.N., Hohmann M.S., et al. Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome. Lupus 2011; 20(13):1356−64.Lozovoy M.A., Simão A.N., Hohmann M.S., et al. Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome. Lupus 2011; 20(13):1356−64.16. Kim H.A., Chun H.Y., Kim S.H., et al. C‑reactive protein gene polymorphisms in disease susceptibility and clinical manifestations of Korean systemic lupus erythematosus. J Rheumatol 2009;36(10):2238−43.Kim H.A., Chun H.Y., Kim S.H., et al. C‑reactive protein gene polymorphisms in disease susceptibility and clinical manifestations of Korean systemic lupus erythematosus. J Rheumatol 2009;36(10):2238−43.17. Enocsson H., Sjöwall C., Skogh T., et al. Interferon‑alpha mediates suppression of C‑reactive protein: explanation for muted C‑reactive protein response in lupus flares? Arthritis Rheum 2009;60(12):3755−60.Enocsson H., Sjöwall C., Skogh T., et al. Interferon‑alpha mediates suppression of C‑reactive protein: explanation for muted C‑reactive protein response in lupus flares? Arthritis Rheum 2009;60(12):3755−60.18. Williams R.C., Harmon M.E., Burlingame R., Du Clos T.W. Studies of serum C‑reactive protein in systemic lupus erythematosus. Rheumatol 2005;32(3):454−61.Williams R.C., Harmon M.E., Burlingame R., Du Clos T.W. Studies of serum C‑reactive protein in systemic lupus erythematosus. Rheumatol 2005;32(3):454−61.19. Plazak W., Pasowicz M., Kostkiewicz M., et al. Influence of chronic inflammation and autoimmunityPlazak W., Pasowicz M., Kostkiewicz M., et al. Influence of chronic inflammation and autoimmunityon coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients. Inflamm Res 2011;60(10):973−80.20. Plazak W., Gryga K., Milewski M., et al. Association of heart structure and function abnormalities with laboratory findings in patients with systemic lupus erythematosus. Lupus 2011;20(9):936−44.Plazak W., Gryga K., Milewski M., et al. Association of heart structure and function abnormalities with laboratory findings in patients with systemic lupus erythematosus. Lupus 2011;20(9):936−44.21. Kiani A.N., Post W.S., Magder L.S., Petri M. Predictors of progression in atherosclerosis overKiani A.N., Post W.S., Magder L.S., Petri M. Predictors of progression in atherosclerosis over2 years in systemic lupus erythematosus. Rheumatology (Oxford) 2011;50(11):2071−9.years in systemic lupus erythematosus. Rheumatology (Oxford) 2011;50(11):2071−9.22. Albar Z., Wijaya L.K. Is there a relationship between serum C‑reactive protein level and dyslipidaemia in systemic lupus erythematosus? Acta Med Indones 2006;38(1):23−8.Albar Z., Wijaya L.K. Is there a relationship between serum C‑reactive protein level and dyslipidaemia in systemic lupus erythematosus? Acta Med Indones 2006;38(1):23−8.23. Bis J.C., Eiriksdottir G., Lu C., еt al. Meta‑analysis of genome‑wide association studies in >80 000 subjects identifies multiple loci for C‑reactive protein levels. Circulation 2011;123(7):731−8.Bis J.C., Eiriksdottir G., Lu C., еt al. Meta‑analysis of genome‑wide association studies in >80 000 subjects identifies multiple loci for C‑reactive protein levels. Circulation 2011;123(7):731−8.24. Kaptoge S., Di Angelantonio E., Lowe G., et al. С‑reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta‑analysis. LancetKaptoge S., Di Angelantonio E., Lowe G., et al. С‑reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta‑analysis. Lancet2010;375(9709):132−40.;375(9709):132−40.25. Dhaun N., Lilitkarntakul P., Macintyre I.M., et al. Urinary endothelin‑1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am J Physiol Renal Physiol 2009;296(6):1477−83.Dhaun N., Lilitkarntakul P., Macintyre I.M., et al. Urinary endothelin‑1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am J Physiol Renal Physiol 2009;296(6):1477−83.26. Sjöwall C., Zickert A., Skogh T., et al. Serum levels of autoantibodies against C‑reactive proteinSjöwall C., Zickert A., Skogh T., et al. Serum levels of autoantibodies against C‑reactive proteincorrelate with renal disease activity and response to therapy in lupus nephritis. Arthritis Res Ther2009;11(6):188.;11(6):188.27. Tan Y., Yu F., Yang H., et al. Autoantibodies against monomeric C‑reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitialTan Y., Yu F., Yang H., et al. Autoantibodies against monomeric C‑reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitiallesions. Hum Immunol 2008;69(12):840−4.28. Киселева А.Г., Орлова Г.М., Бердникова И.А., Фереферова Н.М. Хроническая болезнь почек как фактор риска атеросклероза у больных системной красной волчанкой. Сибирский медицинский журнал 2009;(1):92−4.Киселева А.Г., Орлова Г.М., Бердникова И.А., Фереферова Н.М. Хроническая болезнь почек как фактор риска атеросклероза у больных системной красной волчанкой. Сибирский медицинский журнал 2009;(1):92−4.29. He C.S., Shi W., Ye Z.M., et al. Cardiovascular risk profile in systemic lupus erythematosus: a cross‑sectional study of 879 patients (in Chinese). Nan Fang Yi Ke Da Xue Xue Bao 2011;31(11):1910−3.He C.S., Shi W., Ye Z.M., et al. Cardiovascular risk profile in systemic lupus erythematosus: a cross‑sectional study of 879 patients (in Chinese). Nan Fang Yi Ke Da Xue Xue Bao 2011;31(11):1910−3.30. Wetterö J., Nilsson L., Jonasson L., Sjöwall C. Reduced serum levels of autoantibodies against monomeric C‑reactive protein (CRP) in patients with acute coronary syndrome. Clin Chim Acta 2009;400(1−2):128−31.Wetterö J., Nilsson L., Jonasson L., Sjöwall C. Reduced serum levels of autoantibodies against monomeric C‑reactive protein (CRP) in patients with acute coronary syndrome. Clin Chim Acta 2009;400(1−2):128−31.31. Laiho K., Tiitinen S., Teppo AM., et al. Serum C‑reactive protein is rarely lost into urine in patients with secondary amyloidosis and proteinuria. Clin Rheumatol 1998;17(3):234−5.Laiho K., Tiitinen S., Teppo AM., et al. Serum C‑reactive protein is rarely lost into urine in patients with secondary amyloidosis and proteinuria. Clin Rheumatol 1998;17(3):234−5.